肿瘤微环境
癌症研究
化学
重编程
串扰
免疫系统
阿霉素
内化
细胞生物学
药理学
肿瘤缺氧
药品
活性氧
癌细胞
免疫增强剂
自噬
药物输送
微泡
细胞毒性T细胞
葡萄糖氧化酶
透明质酸
DNA损伤
免疫疗法
抗药性
膀胱癌
胆固醇
癌症免疫疗法
缺氧(环境)
NADPH氧化酶
免疫检查点
小RNA
硫酸软骨素
毒品携带者
肿瘤进展
癌症
多重耐药
联合疗法
作者
Jing Wang,Xianchun Fu,Han Zhang,Zhi Liu
出处
期刊:Small
[Wiley]
日期:2025-09-30
卷期号:21 (46): e09075-e09075
被引量:8
标识
DOI:10.1002/smll.202509075
摘要
Abstract Chemoresistance remains a daunting challenge in bladder cancer therapy, primarily driven by cholesterol‐enriched rigid membranes that impede drug penetration and an immunosuppressive tumor microenvironment (TME) that evades immune surveillance. Herein, a biomimetic nanoplatform (DOX@COD‐ZCM@CS, DCZCMC) is reported engineered to orchestrate metabolic‐immunological crosstalk for synergistic reversal of chemoresistance. This integrated system comprises a Zn‐Co metal‐organic framework (Zn‐Co‐MOF, ZCM) core loaded with cholesterol oxidase (COD) and doxorubicin (DOX), surface‐functionalized with chondroitin sulfate (CS) for tumor‐specific targeting. Mechanistically, DCZCMC achieves three‐tiered synergism: 1) COD‐mediated cholesterol depletion (71.5% reduction, 111.2 vs 389.8 µ m in the saline group) disrupts membrane rigidity, augmenting intratumoral drug retention to 87% (vs 39% with free DOX); 2) ZCM converts COD‐generated H 2 O 2 into cytotoxic hydroxyl radicals (·OH), realizing pathological cholesterol‐to‐ reactive oxygen species (ROS) reprogramming for selective tumor oxidation; 3) Zn 2+ release triggers mitochondrial DNA (mtDNA) leakage, activating the cyclic GMP‐AMP synthase‐stimulator of interferon genes (cGAS‐STING) pathway to amplify interferon‐β (IFN‐β) and High Mobility Group Protein 1 (HMGB1) secretion, thereby driving dendritic cells (DCs) maturation and adaptive immune activation. In drug‐resistant xenografts, DCZCMC exhibits exceptional antitumor efficacy (95.6% tumor suppression) without systemic toxicity. This self‐amplifying “metabolic priming‐immune activation” cascade represents a paradigm shift in overcoming chemoresistance, offering a transformative strategy for bladder cancer and other malignancies characterized by metabolic‐immunological dysregulation.
科研通智能强力驱动
Strongly Powered by AbleSci AI